Skip to main content

Table 3 Frequent (≥20%) reported adverse events across dose levels 3–4 that were considered related to both foretinib and lapatinib

From: A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer

  Adverse events
Grade 1–2
Grade 3 Grade 4
Dose level 3 (n = 6)    
Diarrhea 6  
Nausea 6  
Vomiting 4 1
Fatigue 5  
Anorexia 5  
Proteinuria 4  
Thromboembolic 1 2
Anemia 4  
AST and/or ALT elevation 5/6  
Dose level 4 (n = 7)    
Diarrhea 2 5
Nausea 7  
Vomiting 5  
Fatigue 5 2
Anorexia 5  
Proteinuria 2 1
Edema (limbs) 2  
Myalgia 3  
Hypertension 4  
Anemia 2  
AST and/or ALT elevation 5/4 2/3
  1. AST aspartate aminotransferase, ALT alanine aminotransferase